BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 20001754)

  • 1. Inherent and iatrogenic immune defects in hairy cell leukemia: revisited.
    Dasanu CA; Ichim TE; Alexandrescu DT
    Expert Opin Drug Saf; 2010 Jan; 9(1):55-64. PubMed ID: 20001754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
    Rucińska M; Machaczka M; Załuska A; Skotnicki AB
    Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trials of pentostatin (Nipent) in hairy cell leukemia.
    Kraut EH
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):27-31. PubMed ID: 10877048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hairy-cell leukemia: current views.
    Tallman MS; Peterson LC; Hakimian D; Gillis S; Polliack A
    Semin Hematol; 1999 Apr; 36(2):155-63. PubMed ID: 10319384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
    Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years.
    Else M; Ruchlemer R; Osuji N; Del Giudice I; Matutes E; Woodman A; Wotherspoon A; Swansbury J; Dearden C; Catovsky D
    Cancer; 2005 Dec; 104(11):2442-8. PubMed ID: 16245328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
    Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
    Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
    Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
    Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of hairy cell leukemia with unusual immunologic disorders.
    Dorsey JK; Penick GD
    Arch Intern Med; 1982 May; 142(5):902-3. PubMed ID: 7082114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
    Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
    Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cladribine in hairy cell leukemia.
    Belani R; Saven A
    Hematol Oncol Clin North Am; 2006 Oct; 20(5):1109-23. PubMed ID: 16990111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current treatment options in hairy cell leukemia and hairy cell leukemia variant.
    Robak T
    Cancer Treat Rev; 2006 Aug; 32(5):365-76. PubMed ID: 16781083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy.
    Vedantham S; Gamliel H; Golomb HM
    Cancer Res; 1992 Mar; 52(5):1056-66. PubMed ID: 1737364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hairy cell leukemia: an elusive but treatable disease.
    Wanko SO; de Castro C
    Oncologist; 2006; 11(7):780-9. PubMed ID: 16880237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Successful use of cladribine in the treatment of an elderly woman with typical hairy cell leukemia].
    Terasaki Y; Okumura H; Hirose A; Ishiura Y; Yokawa S; Saito K; Nakao S
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1885-8. PubMed ID: 18030031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of a patient with hairy cell leukemia and pentostatin-induced autoimmune thrombocytopenia with rituximab.
    Hensel M; Ho AD
    Am J Hematol; 2003 May; 73(1):37-40. PubMed ID: 12701118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia.
    Else M; Osuji N; Forconi F; Dearden C; Del Giudice I; Matutes E; Wotherspoon A; Lauria F; Catovsky D
    Cancer; 2007 Nov; 110(10):2240-7. PubMed ID: 17886250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical overview of pentostatin (Nipent) use in lymphoid malignancies.
    Dearden CE; Matutes E; Catovsky D
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):22-6. PubMed ID: 10877047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hairy cell leukemia in young patients].
    Al'-Radi LS; Samoĭlova RS; Tikhonova LIu; Diagileva OA; Naumova IN; Kaplanskaia IB; Varlamova EIu
    Ter Arkh; 2008; 80(12):53-8. PubMed ID: 19227908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hairy cell leukemia: a report of 10 cases in Japan and characterization of anti-hairy cell sera.
    Kitani T; Machii T; Inoue R; Kanakura Y
    Jpn J Clin Oncol; 1983 Sep; 13(3):497-509. PubMed ID: 6645081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.